Tien Le


Tien Le
Full Professor, Gynecologic Oncology Fellowship program director and Professor - Fellowship Program Director


Room: 501 Smyth Road , Ottawa, Ontario K1H 8L6

Fax: 613-737-8828

Image of Tien Le


Dr. Le graduated from the University of Toronto in 1989 and completed his residency in general Obstetrics/Gynecology and subspecialty fellowship training in Gynecologic Oncology at the University of Manitoba in 1997. He is presently appointed as full Professor at the University of Ottawa and has a full time clinical practice focusing in Gynecologic Oncology including surgical , systemic therapies and novel clinical trials for treatment of gynecologic cancers.

Dr. Le is the current subspecialty training program director in the division. Dr. Le has a special interest and expertise in clinical trial design and evaluation, health service research, Quality of life assessments, and radical / robotic minimal invasive procedures.  Since joining the division in 2002, he has initiated a number of prospective studies and published  on a wide range of topics relevant to current gynecologic oncology practice such as evaluation of screening strategies in patients on Tamoxifen with respect to endometrial cancer, Quality of Life assessments in endometrial cancer patients treated with surgery and radiation therapies, neoadjuvant chemotherapy in ovarian cancer, and a number of investigative novel chemotherapy research protocols. He also serves as invited reviewers and sit on a number of editorial boards of high impact journals nationally and internationally.

Nationally, Dr. Le has been an active member of the Society of Gynecologic Oncologist of Canada (GOC). He is actively involved with the Gynecologic Cancer Evidence-based Series (EBS) and Practice Guidelines (PG) committee of Cancer Care Ontario. He also serve as expert consultant to the CMPA, Cancer Care of Ontario, and Co Chair the clinical expert guidance panel for the Canadian Agency for Drugs and Technologies in Health / pCODR.

Patient Care Philosophy

Evidence based application of new emerging knowledge and technologies to improve the care of cancers patients maximizing treatment effectiveness and minimizing toxicities  

Selected Publications

  • A. Covens, E. Vella, E. Kennedy, C. Reade, W. Jimenez, T. Le. “Sentinel Lymph Node Biopsy in Vulvar Cancer: Systematic Review, Meta-Analysis and Guideline Recommendations”. Gynecologic Oncology, May 2015; 137(2015): 351-361
  • N. Al Mutairi, T. Le. Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial ovarian Cancer? An Exploratory Analysis, International Journal of Gynecological Cancer, 2014;24(3):461-467.
  • C. Giede, T. Le, P. Power and the SOGC/GOC/SCC Policy And Practice Guidelines Committee. The Role of Surgery in Endometrial Cancer, JOGC April 2013, 35(4):370-371.
  • T. Le, H. Latifah, L. Jolicoeur, J. Weberpals, W. Faught, L. Hopkins, M. Fung Kee Fung. Does Intraperitoneal Chemotherapy Benefit Optimally Debulked Epithelial Ovarian Cancer Patients After Neoadjuvant Chemotherapy?, Gynecologic Oncology, June 2011;121(3):451-454.
  • T. Le, C. Menard, R. Samant, C. E, L. Hopkins, W. Faught, M. Fung Kee Fung. Longitudinal Assessments of Quality of Life in Endometrial Cancer Patients: Effect of Surgical Approach and Adjuvant Radiotherapy. (In press– International Journal of Radiation Oncology, Biology, Physics, 2009;75(3):795-802.
Back to top